KALAMAZOO, Mich., March 23, 2018 /PRNewswire/ -- Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® system, today announced that the Company has submitted a request to the Securities and Exchange Commission to withdraw its S-1 Registration Statement (File No. 333-222991) (the "Registration Statement") on file with the U.S. Securities and Exchange Commission (the "SEC"). The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.
Medizone requested permission to withdraw the Registration Statement to allow the company to amend certain terms of the previously announced Equity Purchase Agreement, dated January 31, 2018, with L2 Capital, LLC ("L2") and SBI Investments LLC, 2014-1 ("SBI" and together with L2, the "Investors"), pursuant to which the Investors committed to purchase in the aggregate, up to $10,000,000 of value of our Common Stock and to re-file a registration statement following the amendment. The terms of the Equity Purchase Agreement have been amended and Medizone intends to re-file a registration statement on Form S-1 as soon as practicable.
About Medizone International, Inc.
Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H2O2) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.
For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
SOURCE Medizone International, Inc.